A phase III randomized controlled trial and economic evaluation of Stereotactic Ablative Radiotherapy (SABR) for Comprehensive treatment of OligoMETastatic (1-3 metastases) cancer: SABR-COMET-3

立体定向消融放射治疗 (SABR) 综合治疗寡转移性（1-3 个转移）癌症的 III 期随机对照试验和经济评价：SABR-COMET-3

• 批准号: 409329
• 负责人: Olson Robert A
• 金额: $ 50.95万
• 依托单位: BC Cancer, part of PHSA (Centre for the North)
• 依托单位国家: 加拿大
• 项目类别: Operating Grants
• 财政年份: 2019
• 资助国家: 加拿大
• 起止时间: 2019-09-01 至 2025-09-01
• 项目状态: 未结题
• 来源: https://webapps.cihr-irsc.gc.ca/decisions/p/project_details.html?applId=409329&lang=en
• 关键词: Biomarkers; Cost-Effectiveness/Cost-Utility; Metastatic Cancers; Oligometastatic Disease/State; Overall Survival; Progression-Free Survival; Quality Of Life; Quality-Adjusted Life Years; Stereotactic Radiotherapy; Toxicity

While systemic therapy, such as chemotherapy, has been the mainstay of treatment for metastatic cancer (i.e. cancer that has spread to distant organs such as lung, liver, brain, or bone), there is emerging evidence that ablative treatment (e.g. surgery or

虽然全身治疗，如化疗，一直是治疗转移性癌症（即癌症已扩散到远处器官，如肺、肝、脑或骨）的主要方法，但越来越多的证据表明，消融治疗（如手术或其他治疗方法）可能会导致癌症复发